Johnson & Johnson $JNJ Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 13.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,497 shares of the company’s stock after purchasing an additional 14,400 shares during the period. Intech Investment Management LLC’s holdings in Johnson & Johnson were worth $18,711,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Paragon Capital Management LLC grew its holdings in Johnson & Johnson by 14.4% in the 2nd quarter. Paragon Capital Management LLC now owns 34,807 shares of the company’s stock valued at $5,317,000 after buying an additional 4,373 shares during the period. Cetera Investment Advisers grew its holdings in Johnson & Johnson by 0.8% in the second quarter. Cetera Investment Advisers now owns 714,423 shares of the company’s stock valued at $109,128,000 after purchasing an additional 5,450 shares during the period. Fusion Capital LLC increased its position in Johnson & Johnson by 3.2% during the second quarter. Fusion Capital LLC now owns 40,755 shares of the company’s stock worth $6,225,000 after purchasing an additional 1,280 shares during the last quarter. WealthShield Partners LLC raised its stake in Johnson & Johnson by 6.1% during the second quarter. WealthShield Partners LLC now owns 6,346 shares of the company’s stock worth $969,000 after purchasing an additional 366 shares during the period. Finally, OmniStar Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 100.7% in the 2nd quarter. OmniStar Financial Group Inc. now owns 23,595 shares of the company’s stock valued at $3,604,000 after purchasing an additional 11,837 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on JNJ. Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a report on Wednesday, October 15th. UBS Group upped their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research note on Tuesday, October 14th. Daiwa America upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Finally, Bank of America lifted their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research report on Wednesday, October 15th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $196.00 on Friday. The firm has a market capitalization of $472.22 billion, a PE ratio of 18.92, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. Johnson & Johnson has a one year low of $140.68 and a one year high of $197.18. The stock’s 50 day moving average price is $185.81 and its 200 day moving average price is $169.94. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion for the quarter. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.